Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heba M Ismail

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Diabetes Care|June 12, 2026
Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect ProfileLaura M Jacobsen, Dave Cuthbertson, Jamie Felton, et al.
Pediatric Diabetes|April 30, 2025
Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 DiabetesTaylor M Triolo, Laura M Jacobsen, David Cuthbertson, et al.
Diabetes Care|August 7, 2021
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet CohortsMichael G Voss, David D Cuthbertson, Mario M Cleves, et al.
Diabetes Care|November 3, 2022
Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at ScreeningEmily K Sims, David Cuthbertson, Jamie L Felton, et al.
Diabetes|August 28, 2025
Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time IntervalEmily K Sims, William E Russell, David Cuthbertson, et al.
Diabetes|November 14, 2025
Baseline Insulin Secretion Determines Response to Abatacept in Stage 1 Type 1 DiabetesAlfonso Galderisi, Alice L J Carr, Peter Taylor, et al.
Diabetes Care|April 15, 2024
Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy TrialsLaura M Jacobsen, David Cuthbertson, Brian N Bundy, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment responseJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Diabetes Care|September 14, 2023
Hydroxychloroquine in Stage 1 Type 1 DiabetesIngrid Libman, Polly J Bingley, Dorothy Becker, et al.
Communications Medicine|October 4, 2023
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic reviewJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Diabetes Care|June 12, 2026
Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect ProfileLaura M Jacobsen, Dave Cuthbertson, Jamie Felton, et al.
Pediatric Diabetes|April 30, 2025
Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 DiabetesTaylor M Triolo, Laura M Jacobsen, David Cuthbertson, et al.
Diabetes Care|August 7, 2021
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet CohortsMichael G Voss, David D Cuthbertson, Mario M Cleves, et al.
Diabetes Care|November 3, 2022
Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at ScreeningEmily K Sims, David Cuthbertson, Jamie L Felton, et al.
Diabetes|August 28, 2025
Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time IntervalEmily K Sims, William E Russell, David Cuthbertson, et al.
Diabetes|November 14, 2025
Baseline Insulin Secretion Determines Response to Abatacept in Stage 1 Type 1 DiabetesAlfonso Galderisi, Alice L J Carr, Peter Taylor, et al.
Diabetes Care|April 15, 2024
Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy TrialsLaura M Jacobsen, David Cuthbertson, Brian N Bundy, et al.
Medrxiv : the Preprint Server for Health Sciences|May 3, 2023
Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment responseJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Diabetes Care|September 14, 2023
Hydroxychloroquine in Stage 1 Type 1 DiabetesIngrid Libman, Polly J Bingley, Dorothy Becker, et al.
Communications Medicine|October 4, 2023
Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic reviewJamie L Felton, Kurt J Griffin, Richard A Oram, et al.
Pageof 7